Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?

International Journal of Cancer

Volumn 129, Issue 9, 2011, Pages 2051-2061

  Matthews, Hayden ^a   Ranson, Marie ^a   Kelso, Michael J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

amiloride; anti metastasis drug; chemotherapy; metastasis; NHE; plasminogen activation system; uPA

Indexed keywords

5 (N,N DIMETHYL)AMILORIDE; ACID SENSING ION CHANNEL; ADENOSINE TRIPHOSPHATASE; AMILORIDE; DOXORUBICIN; IMATINIB; PACLITAXEL; SODIUM PROTON EXCHANGE PROTEIN 1; UROKINASE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; INTESTINE CANCER; LIVER CELL CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; NONHUMAN; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; STOMACH CANCER;

ADMINISTRATION, ORAL; AMILORIDE; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; SODIUM CHANNEL BLOCKERS; SODIUM-HYDROGEN ANTIPORTER; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80052265739     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26156     Document Type: Article

References (78)

1. Sweetman SC, ed. Martindale: the complete drug reference [online]. London: Pharmaceutical Press (Accessed on 20 Feb 2011)
2. Micromedex® Healthcare Series, Drugdex® Evaluations, Amiloride [online]. Thomson Reuters, 2009. Available at: http://www.micromedex.com/. Accessed on 20 Feb 2011.
3. Garty H, Palmer LG,. Epithelial sodium channels: function, structure and regulation. Physiol Rev 1997; 77: 359-96. (Pubitemid 27184343)
4. Sparks RL, Pool TB, Smith NKR, Cameron IL,. Effects of amiloride on tumour growth and intracellular element content of tumour cells in vivo. Cancer Res 1983; 43: 73-7. (Pubitemid 13172797)
5. Tatsuta M, Iishi H, Baba M, Yano H, Iseki K, Uehara H, Nakaizumi A,. Inhibition by amiloride of experimental carcinogenesis induced by azaserine in rat pancreas. Cancer Lett 1996; 106: 23-8. (Pubitemid 26306634)
6. Tatsuta M, Iishi H, Baba M, Yano H, Sakai N, Uehara H, Nakaizumi A,. Chemoprevention by amiloride against experimental hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Cancer Lett 1997; 119: 109-13. (Pubitemid 27464672)
7. Tatsuta M, Iishi H, Baba M, Uehara H, Nakaizumi A, Taniguchi H,. Inhibition by amiloride of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Br J Cancer 1993; 67: 1011-14. (Pubitemid 23147494)
8. Tatsuta M, Iishi H, Baba M, Uehara H, Nakaizumi A,. Chemoprevention by amiloride of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis 1995; 16: 941-2.
9. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R,. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997; 57: 559-63. (Pubitemid 27085630)
10. Evans DM, Sloan-Stakleff K,. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am Surg 2000; 66: 460-4. (Pubitemid 30252477)
11. Evans DM, Sloan-Stakleff K,. Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin Exp Metastasis 2004; 21: 339-46. (Pubitemid 39434544)
12. Kellen JA, Mirakian A, Kolin A,. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 1988; 8: 1373-6. (Pubitemid 19045931)
13. Evans DM, Sloan-Stakleff KD,. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis 1998/1999; 18: 252-60. (Pubitemid 30223701)
14. Evans DM, Sloan-Stakleff K, Arvan M, Guyton DP,. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin Exp Metastasis 1998; 16: 353-7. (Pubitemid 28255530)
15. Iishi H, Tatsuta M, Baba M, Yano H, Uehara H, Nakaizumi A,. Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int J Cancer 1995; 63: 716-19.
16. + exchanger. Biochem J 2007; 401: 623-33. (Pubitemid 46219256)
17. Beltrán AR, Ramírez MA, Carraro-Lacroix LR, Hiraki Y, Rebouças NA, Malnic G,. NHE1, NHE2, and NHE4 contribute to regulation of cell pH in T84 colon cancer cells. Pflügers Arch Eur J Physiol 2008; 455: 799-810. (Pubitemid 350265616)
18. Yamagata M, Tannock IF,. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer 1996; 73: 1328-34. (Pubitemid 26175663)
19. + exchanger for tumor growth. Cancer Res 1989; 49: 205-21.
20. + exchanger 1 by 5-(N ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett 2010; 295: 198-204.
21. Martin GR, Jain RK,. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 1994; 54: 5670-4. (Pubitemid 24346265)
22. Rofstad EK, Mathiesen B, Kindem K, Galappathi K,. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66: 6699-707. (Pubitemid 44085627)
23. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004; 279: 26991-7007. (Pubitemid 38812535)
24. + exchanger blockade inhibits the expression of vascular endothelial growth factor in SGC7901 cells. Oncol Rep 2010; 23: 79-87.
25. + exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 2009; 10: 737-53.
26. + exchanger. Leuk Res 2007; 31: 507-14. (Pubitemid 46198933)
27. + exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-95. (Pubitemid 41400778)
28. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ,. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res 2009; 29: 2127-36.
29. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K,. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treatment Rev 2003; 29: 541-9. (Pubitemid 37428326)
30. + exchange system. Mol Pharmacol 1984; 25: 131-6. (Pubitemid 14223263)
31. + and the interaction with amiloride derivatives. Biochemistry 2003; 42: 15361-8. (Pubitemid 38031735)
32. Chen Y-X, O'Brien ER,. Ethyl isopropyl amiloride inhibits smooth muscle cell proliferation and migration by inducing apoptosis and antagonising urokinase plasminogen activator activity. Can J Physiol Pharmacol 2003; 81: 730-9.
33. Kleyman TR, Cragoe EJ, Jr,. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 1988; 105: 1-21.
34. + exchange inhibition induces intracellular acidosis and differentially impairs cell growth and viability of human and rat hepatocarcinoma cells. Toxicol Lett 1999; 106: 215-8.
35. Lee CH, Cragoe EJ, Jr, Edwards AM,. Control of hepatocyte DNA synthesis by intracellular pH and its role in the action of tumor promoters. J Cell Physiol 2003; 195: 61-9. (Pubitemid 36292760)
36. Liu JC-K, Fox MH,. Modification of intracellular pH and thermotolerance development by amiloride. Int J Hyperthermia 1995; 11: 511-23.
37. + antiport function. Radiother Oncol 1996; 40: 75-83. (Pubitemid 26246270)
38. Lyons JC, Ross BD, Song CW,. Enhancement of hyperthermia effect in vivo by amiloride and DIDS. Int J Radiat Oncol Biol Phys 1993; 25: 95-103. (Pubitemid 23029779)
39. Song CW, Lyons JC, Griffin RJ, Makepeace CM, Cragoe EJ, Jr,. Increase in thermosensitivity of tumor cells by lowering intracellular pH. Cancer Res 1993; 53: 1599-601. (Pubitemid 23113237)
40. Kitai R, Kabuto M, Kubota T, Kobayashi H, Matsumoto H, Hayashi S, Shioura H, Ohtsubo T, Katayama K, Kano E,. Sensitization to hyperthermia by intracellular acidification of C6 glioma cells. J Neurooncol 1998; 39: 197-203. (Pubitemid 28482555)
41. Ye J-H, Gao J, Wu Y-N, Hu Y-J, Zhang C-P, Xu T-L,. Identification of acid-sensing ion channels in adenoid cystic carcinomas. Biochem Biophys Res Commun 2007; 355: 986-92. (Pubitemid 46389504)
42. Kapoor N, Bartoszewski R, Qadri YJ, Bebok Z, Bubien JK, Fuller CM, Benos DJ,. Knockdown of ASIC1 and epithelial sodium channel subunits inhibits glioblastoma whole cell current and cell migration. J Biol Chem 2009; 284: 24526-41.
43. Owen CS, Pooler PM, Wahl ML, Coss RA, Leeper DB,. Altered proton extrusion in cells adapted to growth at low extracellular pH. J Cell Physiol 1997; 173: 397-405. (Pubitemid 27481097)
44. + channels contribute to regulatory volume increases in human glioma cells. Am J Physiol Cell Physiol 2007; 293: 1181-5.
45. Berdiev BK, Xia J, McLean LA, Markert JM, Gillespie GY, Mapstone TB, Naren AP, Jovov B, Bubien JK, Ji H-L, Fuller CM, Kirk KL, et al., Acid-sensing ion channels in malignant gliomas. J Biol Chem 2003; 278: 15023-34. (Pubitemid 36799835)
46. + exchanger. Blood 2000; 95: 1427-34. (Pubitemid 30099857)
47. Cho Y-L, Lee K-S, Lee S-J, Namkoong S, Kim Y-M, Lee H, Ha K-S, Han J-A, Kwon Y-G, Kim Y-M,. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Biochem Biophys Res Commun 2005; 326: 752-8. (Pubitemid 39655984)
48. Kim KM, Lee YJ,. Role of HER2/neu signalling in sensitivity to tumor necrosis factor related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride. J Cell Biochem 2005; 96: 376-89. (Pubitemid 41437869)
49. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ,. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 2007; 97: 646-53. (Pubitemid 47339892)
50. + exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. Breast Cancer Res 2004; 6: R616-28.
51. + exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. J Biol Chem 2005; 280: 27173-8. (Pubitemid 41040756)
52. Ploug M,. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-528. (Pubitemid 36758313)
53. Croucher DR, Saunders DN, Lobov S, Ranson M,. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008; 8: 535-45. (Pubitemid 351881848)
54. Blasi F, Sidenius N,. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 84: 1923-30.
55. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratoz F, Ferno M, Eppenberger-Castori S, Sweep CGJF, Ulm K, et al., Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28. (Pubitemid 34121291)
56. Ulisse S, Baldini E, Sorrenti S, D'Armiento M,. The urokinase plasminogen activation system: a target for anti-cancer therapy. Recent Pat Anti-Canc 2009; 9: 32-71.
57. Tyndall JDA, Kelso MJ, Clingan P, Ranson M,. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. Recent Pat Anticancer Drug Discov 2008; 3: 1-13. (Pubitemid 351223205)
58. Rockway TW, Giranda VL,. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 2003; 9: 1483-98. (Pubitemid 36758312)
59. Phase I and Phase II with MESUPRON. Accessed on Feb 15, 2011.
60. Vassalli J-D, Belin D,. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187-91.
61. Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sperl S, Stürzebecher J, Jacob U,. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol 2000; 301: 465-75.
62. Helenius MA, Saramäki OR, Linja MJ, Tammela TLJ, Visakorpi T,. Amplification of urokinase gene in prostate cancer. Cancer Res 2001; 61: 5340-4. (Pubitemid 32694906)
63. Ray P, Bhatti R, Gadarowski J, Bell N, Nasruddin S,. Inhibitory effects of amiloride on the urokinase plasminogen activators in prostatic cancer. Tumor Biol 1998; 19: 60-4. (Pubitemid 28026930)
64. Oka N, Okumurab Y, Kanayamaa H-O, Izakia H, Okamotoa M, Kidob H, Kagawaa S,. Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. Eur Urol 2003; 44: 737-41. (Pubitemid 37542934)
65. Wang Y, Jones CJ, Dang J, Liang X, Olsen JE, Doe WF,. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 1994; 353: 138-42. (Pubitemid 24319814)
66. Hegde M, Roscoe J, Cala P, Gorin F,. Amiloride kills malignant glioma cells independent of its inhibition of the sodium-hydrogen exchanger. J Pharmacol Exp Ther 2004; 310: 67-74. (Pubitemid 38812696)
67. Alliegro MC, Alliegro MA, Cragoe EJ, Glaser BM,. Amiloride inhibition of angiogenesis in vitro. J Exp Zool 1993; 267: 245-52.
68. Avery RL, Connor TB, Farazdaghi M,. Systemic amiloride inhibits experimentally induced neovascularisation. Arch Ophthalmol 1990; 108: 1474-6. (Pubitemid 20344707)
69. Chang W-H, Liu T-C, Yang W-K, Lee C-C, Lin Y-H, Chen T-Y, Chang J-G,. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-Ab/T315I mutant cells to imatinib. Cancer Res 2011; 71: 383-92.
70. Reshkin SJ, Bellizzi A, Cardone RA, Tommassino M, Casavola V, Paradiso A,. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003; 9: 2366-73. (Pubitemid 36687664)
71. + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 2005; 115: 924-9. (Pubitemid 40791833)
72. Sparfel L, Huc L, Vee ML, Desille M, Lagadic-Gossmann D, Fardel O,. Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives. Biochem Pharmacol 2004; 67: 1711-19. (Pubitemid 38479849)
73. Doppler W, Hofmann J, Maly K, Grunicke HH,. Protection of ehrlich ascites tumor cells against the antiproliferative effect of mechlorethamaine (nitrogen mustard) by 5-N, N dimethylamiloride. Cancer Res 1988; 48: 2454-7.
74. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, de Faire U, Forsen K, Hedner T, Linjer E, Schersten B, Wester P, et al., Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001; 358: 539-44. (Pubitemid 32772729)
75. Wermuth CG,. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004; 47: 1303-14. (Pubitemid 38327456)
76. Cragoe E, Woltersdorf OW, Jr, Bicking JB, Kwong SF, Jones JH,. Pyrazine diuretics. II. N amidino-3-amino-5-substituted 6-halopyrazinecarboxamides. J Med Chem 1969; 10: 66-75.
77. Arnaud CH,. Shotgun approach to drugs. Chem Eng News Jan 24, 2011; 89: 32-3.
78. + exchanger. Eur J Med Chem 2003; 8: 547-54. (Pubitemid 36773859)